Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry

Saturday, April 23, 2022

2:00 PM – 2:15 PM US MT

Location: Convention Center: Mile High Ballroom 4EF

CE: Enduring CME: 0.25

Publication Number: 1485.5

Erica J. Brenner, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States; Xian Zhang, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States; Manasi Agrawal, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Ryan Ungaro, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Jean-Frederic Colombel, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Michael D. Kappelman, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States

Presenting Author(s)

Erica J. Brenner, MD, MSCR
Pediatric Gastroenterologist
University of North Carolina at Chapel Hill School of Medicine, North Carolina, United States

Full Presentation

Participants should be aware of the following financial/non-financial relationships:

Erica J. Brenner, MD, MSCR: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Xian Zhang, Zhang, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Manasi Agrawal, MD, MS: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Ryan Ungaro, MD MS: ● AbbVie (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).
● Bristol Myers Squibb (Currently Ongoing) (Products/Services: Advisory Committee).
● Janssen (Currently Ongoing) (Products/Services: Consultant).
● Pfizer (Ended In the Past 24 Months) (Products/Services: Advisory Committee).
● Takeda (Ended In the Past 24 Months) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness).

Jean-Frederic Colombel, MD: ● abbvie (Currently Ongoing) (Products/Services: Consultant).
● Allergan (Currently Ongoing) (Products/Services: Consultant).
● Amgen (Currently Ongoing) (Products/Services: Consultant).
● BMS (Currently Ongoing) (Products/Services: Consultant).
● Boehringer Ingelheim (Currently Ongoing) (Products/Services: Consultant).
● Celgene Corporation (Currently Ongoing) (Products/Services: Consultant).
● Eli Lilly (Currently Ongoing) (Products/Services: Consultant).
● Galmed Research (Currently Ongoing) (Products/Services: Consultant).
● Galxo Smith Kline (Currently Ongoing) (Products/Services: Consultant).
● Genentech (Currently Ongoing) (Products/Services: Consultant).
● Imedex (Currently Ongoing) (Products/Services: Consultant).
● Immunic (Currently Ongoing) (Products/Services: Consultant).
● Intestinal Biotech Development (Currently Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).
● Iterative Scopes (Currently Ongoing) (Products/Services: Consultant).
● Janssen Pharmaceuticals (Currently Ongoing) (Products/Services: Consultant).
● Kaleido Biosciences (Currently Ongoing) (Products/Services: Consultant).
● Merck (Currently Ongoing) (Products/Services: Consultant).
● Microba (Currently Ongoing) (Products/Services: Consultant).
● Novartis (Currently Ongoing) (Products/Services: Consultant).
● PBM Capital (Currently Ongoing) (Products/Services: Consultant).
● Pfizer (Products/Services: Consultant).
● Sanofi (Currently Ongoing) (Products/Services: Consultant).
● Takeda (Currently Ongoing) (Products/Services: Consultant).
● TiGenix (Currently Ongoing) (Products/Services: Consultant).
● Vifor (Currently Ongoing) (Products/Services: Consultant).

Michael D. Kappelman, Kappelman, MD, MPH: ● Abbvie (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).
● Janssen (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).
● Lilly (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).
● Pfizer (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).
● Takeda (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).